CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 96 enrolled
Drug / intervention
Dexamethasone, 0.4mg +1 moredrug
Likely dose
Dexamethasone, 0.4mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04050865
NCT04050865Phase 3Completed
CompareCT.gov

CLN-0052, A Multi-Center, Randomized, Double-Masked, Vehicle Controlled Phase 3 Study Evaluation the Efficacy and Safety of OTX-DP for the Treatment of Allergic Conjunctivitis Using a Modified Conjunctival Allergen Challenge Model (Ora-CAC®)

Ocular Therapeutix, Inc.·interventional·Posted Aug 8, 2019·Updated Oct 7, 2021

In Brief

A Phase 3 clinical trial evaluating Dexamethasone, 0.4mg and Placebo plug with no drug for Allergic Conjunctivitis. Completed, enrolled 96 participants across 6 sites.

Detailed Summary

The objective of the study is to evaluate the efficacy and safety of OTX-DP as a dexamethasone ophthalmic insert when placed in the canaliculus of the eyelid for the treatment of the signs and symptoms of allergic conjunctivitis.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAllergic Conjunctivitis
CountriesUnited States
Collaborators--

Timeline

Phase 3CompletedFinished
2020202120222023202420252026
First PostedAug 8, 2019
Enrollment StartAug 5, 2019
Primary CompletionFeb 28, 2020
TodayJul 2, 2026
Enrollment to primary: 7 monthsPosted 6.9 years ago

Interventions

Dexamethasone, 0.4mgdrug

Ophthalmic Insert

Placebo plug with no drugdevice

Ophthalmic Insert